Abstract
Botulinum toxin type A (Botox®) interferes with acetylcholine release from nerve terminals causing temporary paralysis of the injected muscles. The pioneering work over 25 years ago was for strabismus. In 1989, it was approved for blepharospasm, hemifacial spasm, torticollis, and strabismus. Since then, it has been approved for cosmetic treatment of the glabellar furrows and axillary hyperhydrosis.
You have full access to this open access chapter, Download chapter PDF
Similar content being viewed by others
Keywords
- Botox
- Botulinum
- Toxin
- Incobotulinum toxin
- Onabotulinum toxin
- Cosmetic
- Functional
- Medical
- Glabellar
- Blepharospasm
- Acetylcholine
OnabotulinumtoxinA (e.g., Botox®) interferes with acetylcholine release from nerve terminals causing temporary paralysis of the injected muscles. The pioneering work of ophthalmologists Scott et al. over 25 years ago was for strabismus. In 1989, it was approved for blepharospasm, hemifacial spasm, torticollis, and strabismus (Scott 2004). Since then, it has been approved for cosmetic treatment of the glabellar furrows, primary axillary hyperhidrosis, and migraine headaches. Botox® has become the number one cosmetic procedure and is widely used to treat rhytids of the glabella; forehead; eyelids; and nasal, cervical, and perioral areas. Off-label oculofacial uses include: hyperkinetic wrinkles of the face, hyperlacrimation, eyelid retraction, spastic entropion, blepharoptosis, muscle-tension (stress) headaches, digital Raynaud’s syndrome findings, and improving symmetry for facial palsy. Since the FDA approval of onabotulinumtoxinA, several other serotypes have been approved. In general, their adoption has been more limited due to dosing conversion requirements and slightly different performance characteristics. However, Xeomin® incobotulinumtoxinA does not require refrigeration until reconstitution is performed and doses similarly to Botox®. Zinc/phytase combination may improve effect/longevity particularly in elderly functional patients, which might be considered in these patients that have always had or start showing diminished effect or duration (Koshy et al. 2012).
References
Koshy JC, Sharabi SE, Feldman EM, Hollier Jr LH, Patrinely JR, Soparkar CN. Effect of dietary zinc and phytase supplementation on botulinum toxin treatments. J Drugs Dermatol. 2012;11(4):507–12.
Scott AB. Development of botulinum toxin therapy. Dermatol Clin. 2004;22(2):131–3.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Burroughs, J.R., Anderson, R.L. (2015). Introduction to Botulinum Toxin. In: Hartstein, MD, FACS, M., Massry, MD, FACS, G., Holds, MD, FACS, J. (eds) Pearls and Pitfalls in Cosmetic Oculoplastic Surgery. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1544-6_113
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1544-6_113
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1543-9
Online ISBN: 978-1-4939-1544-6
eBook Packages: MedicineMedicine (R0)